At Elpiscience, we aim to forge long-term, mutually beneficial strategic relationships with leading biopharmaceutical companies and academic institutions to accelerate the development of potentially transformative cancer immunotherapies. Our entrepreneurial culture and unique operational advantages enable nimble decision-making and highly collaborative partnerships to efficiently drive global immuno-oncology innovation.
In January 2021 we entered into an exclusive licensing agreement with TRIGR Therapeutics, now part of Compass Therapeutics, for the development, manufacture and commercialization of ES104/TR009, an investigational bispecific antibody targeting VEGF and DLL4, in China.
In May 2020 we entered a clinical collaboration with Junshi Biosicences to evaluate the safety, tolerability and potential early efficacy signal of ES102, a next generation OX40 agonistic antibody, in combination with toripalimab (TUOYI®), an anti-PD-1 mAb and immune checkpoint inhibitor for the treatment of patients with advanced solid tumors and hematological tumors.
Elpiscience is eager to partner with oncology innovators who share our values and focus to accelerate the development of potentially transformative immunotherapies to benefit cancer patients worldwide.